8-K current report · filed Oct 20, 2026

Vertex Pharmaceuticals (VRTX) 8-K Current Report: October 20, 2026

Item 5.02VRTX overview

Short answer

Vertex Pharmaceuticals (VRTX) filed an 8-K current report with the SEC on October 20, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Daniel Brennan appointed director on October 20, 2026, expanding the Board from 10 to 11 members.

Vertex Pharmaceuticals 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Daniel Brennan appointed director on October 20, 2026, expanding the Board from 10 to 11 members
  • Audit and Finance Committee addition strengthens financial oversight with former Boston Scientific CFO experience
  • $400,000 restricted stock unit award, vesting in October 2027
  • No reportable related-party transactions or appointment arrangements disclosed

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Vertex Pharmaceuticals 8-K filings

Get the next VRTX 8-K as it lands

Follow VRTX for push alerts, or ask the research agent what this filing means.